Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
In Focus channel feed
Scientists are finally learning how to design proteins from scratch. Drug development may never be the same
4 years ago
People
Discovery
Is this Silicon Valley duo the future of biotech?
4 years ago
People
AI
Can this tick biologist and her team of ‘weirdo science’ enthusiasts change the future of scientific research?
4 years ago
People
Discovery
'Empathy and love were not shown’: The story behind Taysha’s layoffs, one of dozens of biotechs suffering this year’s bear market
4 years ago
Cell/Gene Tx
After Covid-19 success, patients with the world’s ‘most stigmatized’ infection push for their own Operation Warp Speed
4 years ago
Chirps, chats and Clubhouses: First-time biotech founders turn to social media for advice, investors and recruitment
4 years ago
Startups
Inside the race to make psychedelics 'mainstream medicines'
4 years ago
R&D
Ahead of FDA committee to discuss new ALS drug, the jury remains out on how much benefit is enough for approval
4 years ago
R&D
FDA+
Covid vaccines and drugs are free. But for many immunocompromised patients, protection comes at a cost
4 years ago
Coronavirus
Biopharma has hyped AI for years. But as the first trials get underway, experts try to manage expectations
4 years ago
AI
Small biotechs with big drug ambitions threaten to upend the traditional drug launch playbook
4 years ago
Marketing
A new cancer immunotherapy brings cautious hope for a field long awaiting the next big breakthrough
4 years ago
R&D
How a tiny Swiss lab and two old blood samples created one of the only effective drugs against Omicron (and why we have so little of it)
4 years ago
Coronavirus
Inside the multibillion-dollar, Silicon Valley-backed effort to reimagine how the world funds (and conducts) science
4 years ago
Discovery
‘Disappointing’ ViaCyte data raise questions about future of company’s attempted diabetes cure
4 years ago
R&D
Cell/Gene Tx
EQRx wants to turn drug pricing reform on its head. Can it succeed, or will Big Pharma stop it in its tracks?
4 years ago
Pharma
A new antibody treatment offers long-awaited hope for immunocompromised patients, if Omicron doesn't get here first
4 years ago
Coronavirus
Omicron is a test for the next pandemic. Will the world keep making the same mistakes?
4 years ago
Coronavirus
Exclusive: Big-name academics and investors are quietly preparing a slate of new (epi)genome editing companies
4 years ago
Cell/Gene Tx
‘It’s a transformation’: Researchers are taking DeepMind’s groundbreaking protein folding software to places few predicted
4 years ago
Discovery
They had promising gene therapies for their daughter's ultra-rare disease. But how to tell if one worked?
4 years ago
Cell/Gene Tx
Antisense technology changed one devastating disease. Why hasn't it transformed others?
4 years ago
R&D
How China turned the tables on biopharma's global dealmaking
4 years ago
China
Contract research is having a moment right now. Will M&A splashes drive the industry to even greater heights?
4 years ago
Outsourcing
First page
Previous page
3
4
5
6
7
8
Next page
Last page